Commissioner of health directed to study and report on activities to support innovations in cell and gene therapy to treat rare diseases, report required, and money appropriated.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 2 Sponsors

Apr 20, 2026 · House

Author added Torkelson

Mar 9, 2026 · House

Introduction and first reading, referred to Health Finance and Policy

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base In Committee — base rate 2%, measured from MN's completed sessions
Momentum -1 45/100 from the pace of recorded action
Time since last action -22 174 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.